PCI Biotech: CEO resigns to assume new position
28 Marzo 2022 - 6:21AM
PCI Biotech: CEO resigns to assume new position
Oslo (Norway), 28 March 2022 – PCI Biotech (OSE:
PCIB) announces today that CEO, Dr Per Walday has resigned to
assume a new position. Dr Walday has a notice period of six months,
and he will step down from his position by the end of September
2022, or earlier. The Board of Directors will initiate a succession
process.
“On behalf of the entire company, I wish Dr
Walday all the best in his new endeavours and sincerely thank him
for his 14 years period as CEO of PCI Biotech. Per will surely be
missed by us all”, says Hans Peter Bøhn, Chairperson of the Board
of Directors.
“I look forward to assuming a new position but
will thoroughly miss all my fantastic colleagues at PCI Biotech. It
has been a long and exciting journey for me, but it is time to let
someone else take the helm of PCI Biotech. The company has a very
strong and competent team and an exciting technology platform with
strong data supporting applications within important emerging
therapeutic modalities. I am confident that the team will succeed
in delivering value to both patients and shareholders, and I will
follow the company’s path and progress closely”, says Per Walday,
CEO.
For further information, please contact:Hans
Peter Bøhn, Chairperson of the Board of DirectorsEmail:
hpb@samfond.noMobile: +47 9171 1597
About PCI
Biotech
PCI Biotech is a biopharmaceutical clinical stage development
company focusing on development and commercialisation of novel
therapies for the treatment of cancer through its innovative
photochemical internalisation (PCI) technology platform. PCI
induces triggered endosomal release that is used to unlock the true
potential of therapeutic modalities.
The company’s lead programme fimaVacc aims to
enhance immunotherapy in cancer, by triggered endosomal release of
antigens or nucleic acids encoding antigens, or immunostimulatory
factors. Enhancement of relevant immune responses with protein- and
peptide-based vaccines were successfully demonstrated in humans
through an extensive Phase I study in healthy volunteers and a
Phase II study is in planning with the aim to demonstrate
enhancement of immunotherapy for treatment of solid tumours. In the
fimaNAc programme endosomal release is utilised to provide
intracellular delivery of nucleic acids, such as mRNA and RNAi
therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.
For further information, please visit:
www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen
64, N-0379
Oslo
Forward-looking
statements This announcement
may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of
which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024